Clinical Trial: A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

U.S., July 15 -- ClinicalTrials.gov registry received information related to the study (NCT07701993) titled 'A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)' on July 09.

Brief Summary: This study will investigate the safety and efficacy of efimosfermin alfa in participants with compensated cirrhosis due to MASH.

Study Start Date: July 20

Study Type: INTERVENTIONAL

Condition: Metabolic Dysfunction-associated Steatohepatitis

Intervention: DRUG: Efimosfermin alfa

Efimosfermin alfa (subcutaneous injection) will be administered.

DRUG: Placebo

Placebo (subcutaneous injectio...